MIAMI — The selective serotonin reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist vilazodone (Viibryd, Forest Laboratories, Inc), currently approved for the treatment of major depressive disorder (MDD) in adults, is also effective in relieving anxiety symptoms in patients with generalized anxiety disorder (GAD).

The finding, from a double-blind, randomized clinical trial, was presented here at the American Society of Clinical Psychopharmacology (ASCP) 2015 Annual Meeting.

The multicenter study compared vilazodone 20-40 mg/day vs placebo in patients aged 18 to 70 years who had GAD.

Continue Reading

READ FULL ARTICLE Curated publisher From Med Scape